中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2012年
9期
973-975
,共3页
环缩术%原发性深静脉瓣膜功能不全
環縮術%原髮性深靜脈瓣膜功能不全
배축술%원발성심정맥판막공능불전
Encircling constriction%Primary deep venous insufficiency
目的 评估应用股浅静脉瓣膜环缩术治疗原发性下肢深静脉瓣膜功能不全的效果.方法 回顾性总结2004年1月至2011年6月,我院187例(196条肢体)原发性下肢深静脉瓣膜功能不全患者采用股浅静脉第一对瓣膜环缩加曲张浅静脉剥脱术治疗的临床资料.结果 176例(183条肢体)术后随访7个月～8年,中位随访时间63.5个月,随访率94.1％ (176/187)；临床症状明显缓解,疗效良好160条,占随访肢体87.4％( 160/183)；术后出现浅静脉曲张复发4条,占2.2％ (4/183)；轻度肿胀17条,占9.3％ (17/183)；溃疡复发2条,占8％ (2/25).结论 股浅静脉瓣膜环缩术是治疗原发性下肢深静脉瓣膜功能不全的有效方法.
目的 評估應用股淺靜脈瓣膜環縮術治療原髮性下肢深靜脈瓣膜功能不全的效果.方法 迴顧性總結2004年1月至2011年6月,我院187例(196條肢體)原髮性下肢深靜脈瓣膜功能不全患者採用股淺靜脈第一對瓣膜環縮加麯張淺靜脈剝脫術治療的臨床資料.結果 176例(183條肢體)術後隨訪7箇月～8年,中位隨訪時間63.5箇月,隨訪率94.1％ (176/187)；臨床癥狀明顯緩解,療效良好160條,佔隨訪肢體87.4％( 160/183)；術後齣現淺靜脈麯張複髮4條,佔2.2％ (4/183)；輕度腫脹17條,佔9.3％ (17/183)；潰瘍複髮2條,佔8％ (2/25).結論 股淺靜脈瓣膜環縮術是治療原髮性下肢深靜脈瓣膜功能不全的有效方法.
목적 평고응용고천정맥판막배축술치료원발성하지심정맥판막공능불전적효과.방법 회고성총결2004년1월지2011년6월,아원187례(196조지체)원발성하지심정맥판막공능불전환자채용고천정맥제일대판막배축가곡장천정맥박탈술치료적림상자료.결과 176례(183조지체)술후수방7개월～8년,중위수방시간63.5개월,수방솔94.1％ (176/187)；림상증상명현완해,료효량호160조,점수방지체87.4％( 160/183)；술후출현천정맥곡장복발4조,점2.2％ (4/183)；경도종창17조,점9.3％ (17/183)；궤양복발2조,점8％ (2/25).결론 고천정맥판막배축술시치료원발성하지심정맥판막공능불전적유효방법.
Objective To evaluate the therapeutic effect of encircling constriction of superficial femoral vein in the treatment of primary deep venous insuficiency(PDVI).Methods From Jan.2004 to Jun.2011,187 patients( 196 lower extremities)with primary deep venous insufficiency were treated with encircling constriction of venous wall at the first pair of superficial femoral venous valve pulse superficial varicose stripping.Results The 183 limbs in 176 patients were followed-up from 7 months to 8 years,with a mean period for 63.5 months.Ninety-four point one percent of the patients were followed up (176/187).Clinical symptomatic improvement achieved in 87.4％ ( 160/183 ) of the lower extremities.There was 2.2％ ( 4/183 ) of recurrence of the varicose vein,9.3％ ( 17/183 ) of light edema,8％ ( 2/25 ) of recurrence of ulcer.Conclusion Encircling constriction of superficial femoral vein is an effective method in the treatment of primary deep venous valve insufficiency.
